Beyond Donor-Specific Antibodies: Molecular Characterization of Antibody-Mediated Rejection Using Tissue-Based Transcriptomics in Heart Transplantation.
Aug 2026· The Journal of Heart and Lung Transplantation· 1 citation· 51 references
Medicine
TL;DR
Molecular ABMR exhibited similar profiles regardless of HLA-DSA status and, within DSA-negative cases, non-HLA antibody status, and may complement conventional evaluation by refining ABMR phenotyping.
Abstract
Background
Antibody-mediated rejection (AMR) contributes to graft dysfunction after heart transplantation, yet histopathology and circulating donor-specific antibodies (DSA) may incompletely capture intragraft biology. We characterized molecular ABMR by HLA-DSA status and, within DSA-negative cases, non-HLA antibody status.
Methods
We analyzed 579 for-cause endomyocardial biopsies with paired Molecular Microscope Diagnostic System (MMDx) and histopathology. Molecular scores, transcripts, donor-derived cell-free DNA (dd-cfDNA), and gene-expression profiling (GEP) were compared using patient-clustered models with false-discovery-rate correction. Multivariable Cox models evaluated a 2-year composite of death, retransplantation, graft dysfunction (LVEF<50%), or subsequent histologic rejection (ACR≥1B/2R or pAMR≥1).
Results
MMDx-defined ABMR was present in 83 biopsies (14.3%); 30 (36.1%) were DSA-negative. DSA-negative and DSA-positive ABMR had similar ABMR probabilities (0.66 vs 0.66), global rejection scores, dd-cfDNA (0.83% vs 0.63%), GEP (35 vs 33), and transcriptomic profiles. Within DSA-negative ABMR, non-HLA antibodies were detected in 20/30 (66.7%) and associated with higher ABMR probability (0.69 vs 0.63; P=0.041), dd-cfDNA (0.91% vs 0.62%; P=0.048), GEP (35 vs 33; P=0.019), and greater endothelial, ABMR/NK-cell, interferon-γ, and injury-related transcript activation. Histologic-molecular agreement was limited (κ=0.14); 70/83 molecular ABMR biopsies lacked histologic pAMR. In joint models, molecular ABMR, but not pAMR, was associated with higher dd-cfDNA (b=0.38%, P=0.039). Conversely, histologic pAMR independently predicted the composite outcome (adjusted HR 2.68, 95% CI 1.34-5.35; P=0.005), whereas molecular ABMR did not (adjusted HR 0.93, 95% CI 0.56-1.56; P=0.795).
Conclusions
Molecular ABMR exhibited similar profiles regardless of HLA-DSA status. Non-HLA antibodies identified greater activation and dd-cfDNA levels within DSA-negative ABMR. Molecular assessment may complement conventional evaluation by refining ABMR phenotyping.
This review summarizes current concepts in AMR pathogenesis, diagnosis, and emerging therapy, using phenotype-guided assessment to separate expert-consensus practice from randomized evidence, observational experience, and experimental interventions.
Bi-Du Song, Jun-Jie Sun, Chao Hu et al.· Frontiers in Immunology· 0 citations
BACKGROUND
Accurate differentiation of acute rejection (AR) from other causes of graft dysfunction after liver transplantation remains challenging in real-world clinical practice. Although donor-derived cell-free DNA (dd-cfDNA) has emerged as a promising non-invasive biomarker of graft injury, its specificity may be li...
Xue-Chun Zhao, Bo Yang, Hong-Mei Jiang et al.· Clinical Transplantation· 0 citations
Donor-specific antibodies (DSA) are preformed recipient antibodies directed against donor HLA antigens, most frequently observed in haploidentical or mismatched allogeneic hematopoietic cell transplantation (HCT). DSA assessed by multiplexed bead-based immunoassays at mean fluorescence intensity (MFI) values >1 000 are...
Lennart Harland, Semian L. Schüch, Sarah Katzenstein et al.· Cell Transplantation· 0 citations
BACKGROUND AND HYPOTHESIS
Microvascular inflammation (MVI), a histological hallmark of antibody-mediated rejection (AMR), is typically associated with donor-specific antibodies (DSA), but can also occur in their absence. Evidence implicates Natural Killer (NK) cells in DSA-negative MVI, although the mechanisms underlyi...
B. Mordà, A. Akifova, Matthias Diebold et al.· Nephrology, Dialysis and Tra...· 0 citations
Endomyocardial biopsy (EMB) is the gold standard for diagnosing post-heart transplant acute rejection (AR) but is invasive. Donor-derived cell-free DNA (dd-cfDNA) is a promising noninvasive biomarker, yet thresholds for Asian recipients remain undefined. This prospective study enrolled 80 patients, with 299 dd-cfDNA sp...
Donor-derived cell-free DNA (dd-cfDNA) is an emerging non-invasive biomarker with growing potential for monitoring graft health and detecting rejection after liver transplantation. Several studies suggest that dd-cfDNA may provide a sensitive approach for assessing graft injury and immune-mediated rejection, although i...